Take action receives UK MHRA clearance for hESC-derived RPE cell trial for Stargardt’s Macular Dystrophy Advanced Cell Technology, Inc nizagara 100 . ;, a innovator in the field of regenerative medicine, announced today that it has received clearance from the U.K. Medicines and Healthcare items Regulatory Agency to begin with treating patients as part of a Phase 1/2 scientific trial for Stargardt’s Macular Dystrophy using retinal pigment epithelium produced from human being embryonic stem cells . ACT received similar authorization from the Gene Therapy Advisory Committee , which includes responsibility for the ethical oversight of proposals to carry out clinical trials involving gene or stem cell therapies in the U.K. The European Medications Company previously granted Orphan Medication designation for the business’s RPE cell product for use in dealing with SMD.
.. ACT Biotech reports positive interim data from Telatinib Phase 2 trial for advanced gastric cancer ACT Biotech Inc. This proof-of-concept, multi-center, open label trial was made to test the protection and efficacy of full-dose Telatinib, administered continuously, as a first-line treatment in combination with a standard routine of capecitabine and cisplatin in US and European individuals. Based on promising preliminary results in April, 2010, the original planned enrollment of thirty-five patients was expanded to the current forty-eight. Telatinib gets the potential to modification the standard of treatment in this tumor indication.